EMD Serono
One Technology Place
Rockland
MA
02370
United States
Tel: 800-283-8088
Website: https://www.emdserono.com/us-en
241 articles about EMD Serono
-
ZymoGenetics, Inc. (JOBS) Says Merck Serono Discontinues MS Trials
9/29/2009
-
Lpath, Inc. and Merck Serono Extend ASONEP(TM) Collaboration
9/24/2009
-
Merck Serono Fertility Drug May Reduce Hot Flashes in Study
9/17/2009
-
ZymoGenetics, Inc. (JOBS), Merck Serono Arthritis Drug Hits Roadblock
9/14/2009
-
Merck Serono to Present New Data at ECCO/ESMO Oncology Congress Showcasing Leadership in Personalized Cancer Care
9/10/2009
-
Lpath, Inc. Achieves Merck Serono Milestone
8/24/2009
-
Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface Receptors
7/30/2009
-
BioSeek, Inc. and Merck Serono Extend 2008 Agreement
6/10/2009
-
Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management
5/28/2009
-
Merck Serono Champions Personalized Cancer Care With Targeted Therapies
5/15/2009
-
Results at American Society of Clinical Oncology Congress 2009 Highlight Merck Serono's Leadership in Personalizing Cancer Care
5/7/2009
-
Merck Serono Two-Year Phase III Data Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
4/30/2009
-
Merck Serono Cancer Pill 'Offers MS Benefits', Queen Mary School of Medicine Study
4/30/2009
-
Merck Serono Launches Biotech Venture Capital Fund
3/23/2009
-
Provenance Biopharmaceuticals Corp. Announces License Agreement with Merck Serono for the Development and Commercialization of Novel Immunocytokine for the Treatment of Cancer
3/19/2009
-
Merck Serono and Fast Forward, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis; Merck KGaA Will Provide Up to $19 Million
3/18/2009
-
Merck Serono Expands Cilengitide Development Program
3/16/2009
-
Ambrx, Inc. and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
2/24/2009
-
Flamel Technologies Announces Merck Serono's Exercise of Option to License Medusa Technology for Development of an Extended-Release Formulation of a Therapeutic Protein
2/17/2009
-
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
1/23/2009